Drugs / CALY-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04593251 | Sep 2020 → Apr 2024 | celiac disease, eosinophilic esophagitis | Calypso Biotech BV | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CALY-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04593251 ↗ |
| Action | Inhibit | “study of an anti-IL-15 mAb (CALY-002)” NCT04593251 ↗ |
| Modality | Monoclonal antibody | “study of an anti-IL-15 mAb (CALY-002)” NCT04593251 ↗ |
| Route | Intravenous | “1-hour intravenous infusion” NCT04593251 ↗ |
| Target | IL15 | “study of an anti-IL-15 mAb (CALY-002)” NCT04593251 ↗ |